Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.
5 Reasons Why Buying This 6%-Yielding Dividend Stock Could Be a Brilliant Move
Pfizer faces challenges including declining COVID-19 sales and a looming patent cliff. However, the company's growth prospects look good.
Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns
Pfizer's stock has dropped over the last year+ due to declines in revenue and profit from Covid-related products. The company's non-Covid products have shown growth, indicating potential for contin...
This overlooked corner of women's health could be a $350 billion market opportunity
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
Pfizer (PFE) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Pfizer (PFE) stood at $28.22, denoting a +0.75% change from the preceding trading day.
Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study
Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.
What To Know About Adcetris—Pfizer's Cancer Drug Extended Survival For Patients With Common Lymphoma
Pfizer's cancer drug Adcetris extended survival in patients with a common form of lymphoma in a late-stage trial, the company announced Tuesday, supporting Pfizer's efforts to expand into cancer tr...
Pfizer: It's Darkest Before The Dawn, Upgrading To 'Strong Buy'
Pfizer's Q4 FY2023 financials show a significant downturn in consolidated revenues, with a 93% decline in profit for the full year. Sales of Comirnaty and Paxlovid, Pfizer's COVID-related drugs, fe...
Pfizer's drug meets main goal in late-stage blood cancer trial
Pfizer said on Tuesday a combination treatment using its drug, Adcetris, met its main goal of overall survival when tested in patients with a type of blood cancer.
Pfizer bets on cancer drugs to recover from rapid decline of COVID business
Pfizer is pushing to be more involved in cancer drugs after a turbulent year marked by the rapid decline of its COVID business. During a four-hour investor event last week, Pfizer pushed its initat...
2 Dirt Cheap Dividend Stocks to Buy and Hold
Pfizer's slumping revenue is a temporary hiccup considering its incredibly deep pipeline. Viatris has made important changes to its business that should pay off down the road.
1 Bruised Dividend Stock to Buy While It's Cheap, and 1 to Avoid
Just because a stock's price fell does not mean it will stay down forever. Pfizer has a long roadmap for how to regain its recent glory.
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.
Related Companies